EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Open Access · CC BY-NC 4.0

Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P‐Gp: Drug Interaction Studies and Physiologically‐Based Pharmacokinetic Analysis

Rainer Strotmann iD, Christian Lüpfert, Axel Krebs-Brown iD, Alice Ke iD, Matthias Boedding, Jürgen Heuer, Karen Rowland Yeo iD, Lisa Benincosa, Karthik Venkatakrishnan iD

Clinical and Translational Science · 2025

DOI: 10.1111/cts.70273 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2025. Verfasst von Rainer Strotmann und 8 weiteren Autor:innen. Beteiligte Einrichtung: The healthcare business of Merck KGaA, Darmstadt, Germany. Hauptthemen laut MEDLINE: ATP Binding Cassette Transporter, Subfamily B, Member 1, Cytochrome P-450 CYP3A, Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 CYP3A Inhibitors. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 27 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tepotinib is a highly selective, potent, mesenchymal‐epithelial transition factor (MET) inhibitor, approved for the treatment of non‐small cell lung cancer harboring MET exon 14 skipping alterations. This work aimed to investigate the potential for drug–drug interactions with strong inhibitors and inducers of both cytochrome P450 (CYP) 3A4/5 and P‐glycoprotein (P‐gp) with tepotinib. Two clinical studies were conducted to investigate the effect of the strong CYP3A4/P‐gp inhibitor itraconazole (200 mg once daily) (NCT05203822) and the strong CYP3A4/P‐gp inducer carbamazepine (titrated to 300 mg twice daily) (NCT05213481) on the pharmacokinetics of single dose tepotinib 500 mg (450 mg active moiety) in healthy participants. An investigational physiologically‐based pharmacokinetic model, developed leveraging mass balance data, was used to evaluate the mechanisms underlying these interactions. Itraconazole increased tepotinib area under the curve extrapolated to infinity (AUC 0‐∞ ) by 22% (geometric mean ratio [GMR] 122.35%; 90% confidence intervals [CIs] 111.48%, 134.29%), but had no effect on tepotinib C max (GMR 101.53%, 90% CI: 94.00%, 109.67%). Carbamazepine decreased tepotinib AUC 0‐∞ by 35% (GMR 65.15%, 90% CI: 59.80%, 70.88%) and C max by 11% (GMR 89.31%, 90% CI: 83.43%, 95.60%). None of these changes were considered to be clinically relevant. Single doses of tepotinib were considered safe and well tolerated in both studies. The observed pharmacokinetic interactions were consistent with a low (~17%) contribution of CYP3A4 to tepotinib metabolism without a relevant role for P‐gp mediated biliary secretion. The potential of tepotinib to be a victim of modulators of both CYP3A4 and P‐gp at the intended posology is considered low.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ATP Binding Cassette Transporter, Subfamily B, Member 1Cytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsPiperidinesPyridazinesPyrimidinesAdultFemaleHumansMaleMiddle AgedYoung AdultArea Under CurveCarbamazepineDrug InteractionsHealthy VolunteersItraconazoleModels, Biological

Stichwörter der Autor:innen

CYPcancersclinical trialsdrug–drug interactionsinductioninhibitorspharmacokineticsphase Iphysiology‐based pharmacokineticstransporters

Substanzen

ATP Binding Cassette Transporter, Subfamily B, Member 1CarbamazepineCYP3A4 protein, humanCytochrome P-450 CYP3ACytochrome P-450 CYP3A InducersCytochrome P-450 CYP3A InhibitorsItraconazolePiperidinesPyridazinesPyrimidines

Autor:innen und Institutionen

  • The healthcare business of Merck KGaA, Darmstadt, Germany.
  • Certara UK Limited, Simcyp Division, Sheffield, UK.
  • Clinical Services, Nuvisan GmbH, Neu-Ulm, Germany.
  • EMD Serono, Billerica, Massachusetts, USA.

ORCID-Profile: Rainer Strotmann, Axel Krebs-Brown, Alice Ke, Karen Rowland Yeo, Karthik Venkatakrishnan

Zitieren

APA

Strotmann, R., Lüpfert, C., Krebs-Brown, A., Ke, A., Boedding, M., Heuer, J., Yeo, K. R., Benincosa, L., & Venkatakrishnan, K. (2025). Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P‐Gp: Drug Interaction Studies and Physiologically‐Based Pharmacokinetic Analysis. Clinical and Translational Science. https://doi.org/10.1111/cts.70273

Vancouver

Strotmann R, Lüpfert C, Krebs-Brown A, Ke A, Boedding M, Heuer J, et al. Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P‐Gp: Drug Interaction Studies and Physiologically‐Based Pharmacokinetic Analysis. Clinical and Translational Science. 2025. doi:10.1111/cts.70273

BibTeX
@article{Strotmann2025,
  author = {Strotmann, Rainer and Lüpfert, Christian and Krebs-Brown, Axel and Ke, Alice and Boedding, Matthias and Heuer, Jürgen and Yeo, Karen Rowland and Benincosa, Lisa and Venkatakrishnan, Karthik},
  title = {Sensitivity of Tepotinib to Inhibitors or Inducers of CYP3A4 and P‐Gp: Drug Interaction Studies and Physiologically‐Based Pharmacokinetic Analysis},
  journal = {Clinical and Translational Science},
  year = {2025},
  doi = {10.1111/cts.70273}
}
Kostenlos starten →